NCT06580938View on ClinicalTrials.gov

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

July 14, 2025

Study Completion Date

July 14, 2025

Conditions
Non Small Cell Lung CancerBladder CancerRenal Cell CarcinomaMelanomaHead and Neck CancerColorectal Cancer
Interventions
BIOLOGICAL

PF-07921585

IL-12 mutein, solution, administered once every 3 weeks intravenously or subcutaneously

BIOLOGICAL

Sasanlimab

Anti-PD1 antibody solution, administered once every 3 weeks subcutaneously

Trial Locations (8)

34232

Florida Cancer Specialists Sarasota Drug Development Unit, Sarasota

37203

SCRI Oncology Partners, Nashville

49546

START Midwest, Grand Rapids

72703

Highlands Oncology Group, Fayetteville

72758

Highlands Oncology Group, Rogers

72762

Highlands Oncology Group, Springdale

80218

Presbyterian/St. Lukes Medical Center, Denver

Sarah Cannon Research Institute at HealthONE, Denver

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06580938 - A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | Biotech Hunter | Biotech Hunter